Intensive blood pressure lowering reduces severe cerebral oedema risk in acute ischemic stroke patientsLowering Blood Pressure Quickly After Stroke May Reduce Brain Swelling

This study is a secondary analysis of an international, multicentre randomized controlled trial involving patients who had undergone thrombolysis for acute ischemic stroke (AIS). The total population in the blood pressure control arm consisted of 2,196 individuals, with 1,477 patients included in the final analysis. The primary objective was to evaluate the impact of intensive blood pressure management on the development of severe cerebral oedema.

The study compared an intensive blood pressure lowering protocol against a guideline-recommended management strategy. In the control group, the target systolic blood pressure (SBP) was maintained below 180 mm Hg. The intervention focused on two specific hemodynamic parameters: the magnitude of SBP reduction within the first hour after thrombolysis and the degree of SBP variability between 1 hour and 24 hours post-treatment.

The primary outcome measured was severe cerebral oedema, defined as scores of 4 to 6 on a 7-point scale. Regarding the impact of rapid blood pressure reduction, the results showed lower odds of severe cerebral oedema with a larger magnitude of SBP reduction in 1 hour. The reported effect size was an adjusted Odds Ratio (OR) of 0.72 per 10 mm Hg (95% CI 0.53 to 0.98; p=0.04). Conversely, the analysis regarding blood pressure stability showed a shift toward worse cerebral oedema with greater SBP variability between 1 hour and 24 hours. This was quantified as an adjusted OR of 1.27 per 10 mm Hg (95% CI 1.01 to 1.60; p=0.04).

Secondary outcomes included the incidence of intracranial haemorrhage and functional outcomes. Regarding safety and tolerability, the study noted that intracranial haemorrhage was observed as reduced in the intensive blood pressure lowering arm. No specific data regarding serious adverse events or treatment discontinuations were reported.

These results provide a nuanced view of hemodynamic management in AIS. While previous landmark studies have established guidelines for post-thrombolysis blood pressure, this analysis specifically links rapid reduction and stability to the physiological complication of cerebral oedema. The authors noted that the effect sizes observed were small.

Several methodological limitations must be considered when interpreting these data. As a secondary analysis of an original randomized controlled trial, the findings are subject to the inherent constraints of post-hoc analysis. The study also noted the modest nature of the effect sizes. Furthermore, specific follow-up durations and detailed tolerability metrics were not reported.

For clinical practice, these results suggest that rapid lowering of SBP within 1 hour and maintaining stable SBP over a 24-hour period may be associated with less cerebral oedema in patients with thrombolysed acute ischemic stroke. Clinicians may use these findings to inform the timing and consistency of blood pressure targets during the acute phase. Several questions remain unanswered regarding the clinical significance of these specific odds ratios for individual patient management. The exact impact on long-term functional outcomes compared to standard care is not fully detailed in this secondary analysis, and the lack of reported serious adverse event rates limits a full safety profile assessment.